Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals-Reference-Cited by-同舟云学术

Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals

Published:2019-05 Issue: Volume:72 Page:22-40
ISSN:2212-4926
Container-title:Advances in Biological Regulation
language:en
Short-container-title:Advances in Biological Regulation

Author:

Candido Saverio,Abrams Stephen L.,Steelman Linda S.,Lertpiriyapong Kvin,Martelli Alberto M.,Cocco Lucio,Ratti Stefano,Follo Matilde Y.,Murata Ramiro M.,Rosalen Pedro L.,Bueno-Silva Bruno,de Alencar Severino Matias,Lombardi Paolo,Mao Weifeng,Montalto Giuseppe,Cervello Melchiorre,Rakus Dariusz,Gizak Agnieska,Lin Heng-Liang,Libra Massimo,Akula Shaw M.,McCubrey James A.

Funder

East Carolina University

Intesa San Paolo Foundation

Lega Italiana per la Lotta contro i Tumori

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology,Molecular Medicine

Reference110 articles.

1. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells;Abrams;Oncotarget,2017

2. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals;Abrams;Adv. Biol. Regul.,2018

3. Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells;Abrams;Adv. Biol. Regul.,2019